ABOUT
What you missed at the 3rd Covalent Drug Discovery & Development Summit
As covalent inhibitors with improved safety and potency progress from the bench to the clinic, the 2nd Covalent Drug Discovery & Development Summit returned with 3 days jam-packed with industry insights that addressed the most prevalent pain points, such as:
 |
Leveraging lysine-, tyrosine- and histidine-based covalency to unlock hard-to-drug targets |
|
Rationally designing covalent heterobifunction and monovalent small molecules displaying alternative MoAs |
|
Minimizing off-target toxicity of your covalent drugs while building in high target specificity |
|
Accelerating your chemical biology-enabled program against transcription factors, E3 ligases, immunology targets and beyond |
What was included?
Overcome challenges in balancing reactivity and sensitivity with advanced and scalable screening cascades to rationally develop covalent handles and streamline the triage of tractable compounds with insights from Genentech, Scorpion Therapeutics & Covant Therapeutics
Supercharge the discovery of highly selective covalent drugs by advancing chemoproteomic platforms and novel probes to assess pharmacology and mitigate their highly contested off-target safety risks with input from Biogen, Nexo Therapeutics & Lundbeck
Propel the development of novel warheads for covalent screening of histidine, tyrosine and lysine residues to expand the druggable proteome and target novel binding pockets with insights from HYKU Biomedicines, Armida Labs & Bayer
Unlock novel disease indications stemming immunology, inflammatory and CNS conditions by progressing the identification and validation of covalent drugs for hard-to-drug targets beyond KRAS G12C, BTK and EGFR with drug discovery and clinical insights from Novartis, Taiho Pharmaceutical & Covant Therapeutics
Advance covalency beyond irreversible inhibition by tapping into the advancing paradigm of covalent PROTACs, monovalent degraders and highly selective biologics, charting the course for first-in-class drugs with insights from Harvard, Pfizer & Amgen
Who Attended this Meeting?
Were you looking to meet with all the key decision makers in the covalent space, including CXOs, VPs, and Directors of Discovery, Medicinal and Biological Chemistry?
This summit included 3 days focusing on advancing the field and discussing next generation therapeutics. This gathering of covalent drug developers, small molecule experts and key opinion leaders from academia was the perfect opportunity to assess the field, take back actionable insights to your team, and realize the potential of covalent drugs.
